Squamous cell carcinoma of the head and neck. Principles and current concepts of immunotherapy;Plattenepithelkarzinome des kopf-hals-bereichs. Grundlagen und aktuelle konzepte der immuntherapie

HNO

Volumn 53, Issue 3, 2005, Pages 285-298

  Hoffmann, T K ^a   Whiteside, T L ^b   Bier, H ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

Adoptive therapy; Cytokines; Head and neck cancer; Immunotherapy; Tumor vaccine

Indexed keywords

ALPHA INTERFERON; BCG VACCINE; CANCER ANTIBODY; CANCER VACCINE; CYTOKINE; DENDRITIC CELL VACCINE; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 2; LEVAMISOLE; MONOCLONAL ANTIBODY; PICIBANIL; PROTEIN P53;

ADOPTIVE IMMUNOTHERAPY; ADOPTIVE TRANSFER; ANTIBODY RESPONSE; ANTIGENICITY; B LYMPHOCYTE; BCG VACCINATION; BIOLOGICAL THERAPY; CANCER CELL; CANCER CHEMOTHERAPY; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CYTOKINE PRODUCTION; DENDRITIC CELL; FIBROBLAST; GENE THERAPY; HEAD CANCER; HUMAN; IMMUNE DEFICIENCY; IMMUNE FUNCTION TEST; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IMMUNOGENICITY; IMMUNOREACTIVITY; IMMUNOSTIMULATION; LYMPHOKINE ACTIVATED KILLER CELL; MONOCYTE; NATURAL KILLER CELL; NECK CANCER; PRACTICE GUIDELINE; RADIOIMMUNOTHERAPY; REVIEW; SQUAMOUS CELL CARCINOMA; T LYMPHOCYTE;

CANCER VACCINES; GENE THERAPY; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNOTHERAPY; IMMUNOTHERAPY, ADOPTIVE; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES; VACCINATION;

EID: 16844368578     PISSN: 00176192     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00106-004-1167-0     Document Type: Review

References (15)

1. Agarwala S, Vlock D, Johnson JT et al. (1991) Phase II trial of interferon-alpha in locally recurrent or metastatic head and neck cancer: results of ECOG trial P-Z386. Proc Am Soc Clin Oncol 10: 205
2. Albanell J, Rojo F, Averbuch S et al. (2002) Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition. J Clin Oncol 20: 110-124
3. Almand B, Resser JR, Lindman B et al. (2000) Clinical significance of defective dendritic cell differentiation in cancer. Clin Cancer Res 6: 1755-1766
4. Almand B, Clark JI, Nikitina E et al. (2001) Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. J Immunol 166: 678-689
5. Amiel JL, Sancho-Garnier H, Vanderbrouck C et al. (1979) First results of a randomized trial on immunotherapy of head and neck tumors. Recent Results Cancer Res 68: 318-323
6. Armstrong A, Eck SL (2003) EpCAM: A new therapeutic target for an old cancer antigen. Cancer Biol Ther 2: 320-326
7. Balz V, Scheckenbach K, Götte K, Bockmühl U, Petersen I, Bier H (2003) Is the p53 inactivation in squamous cell carcinomas of the head and neck understimated? Analysis of p53 Exons 2-11 and human papillomavirus 16/18 E6 transcripts in 123 unselected tumor specimens. Cancer Res 63: 1188-1191
8. Barrera JL, Verastegui E, Meneses A, Zinser J, dela-Garza J, Hadden JW (2000) Combination immunotherapy of squamous cell carcinoma of the head and neck: a phase 2 trial. Arch Otolaryngol Head Neck Surg 126: 345-351
9. Baselga J, Pfister D, Cooper MR et al. (2000) Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin J Clin Oncol 18: 904-914
10. Baselga J, Rischin D, Ranson M (2002) Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J Clin Oncol 20: 4292-4302
11. Bergler W, Bier H, Ganzer U (1989) The expression of epidermal growth factor receptors in the oral mucosa of patients with oral cancer. Arch Otorhinolaryngol 246: 121-125
12. Berlinger NT (1984) Deficient immunity in head and neck cancer due to excessive monocyte production of prostaglandins. Laryngoscope 94: 1407-1410
13. Bier H, Reiffen KA, Haas I, Stasiecki P (1995) Dose-dependent access of murine anti-epidermal growth factor receptor monoclonal antibody to tumor cells in patients with advanced laryngeal and hypopharyngeal carcinoma. Eur Arch Otorhinolaryngol 252: 433-439
14. Bier H, Hoffmann T (1996) Epidermal growth factor receptor in head and neck squamous cell carcinomas. In: Werner JA., Lippert BM, Rudert HH (eds) Head and neck cancer - advances in basic research. Excerpta Medica Int. Congress Series 1114: 225-234
15. Bier H, Hoffmann T, van Lierop A (1998) Anti- (epidermal growth factor) receptor monoclonal antibodies for the induction of antibody-dependent cell-mediated cytotoxicity against squamous cell carcinoma lines of the head and neck. Cancer Immunol Immunother 46: 167-173